Aaron D. Thome, PhD

Medicine & Life Sciences

1. Amyotrophic Lateral Sclerosis 100%
2. Regulatory T-Lymphocytes 92%
3. Parkinson Disease 91%
4. Microglia 71%
5. Synucleins 70%
6. Alzheimer Disease 68%
7. Inflammation 65%
8. alpha-Synuclein 58%
9. Interleukin-2 41%
10. Acute-Phase Proteins 34%
11. 5-methyl-N-(4-methylpyrimidin-2-yl)-4-(1H-pyrazol-4-yl)thiazol-2-amine 34%
12. metabotropic glutamate receptor 4 25%
13. Major Histocompatibility Complex 24%
14. MHC class II transactivator protein 24%
15. Myeloid Cells 23%
16. Antigen Presentation 22%
17. Disease Progression 22%
18. Chemokine CX3CL1 22%
19. Monocytes 21%
20. Abatacept 21%
21. Dopaminergic Neurons 19%
22. Macrophages 19%
23. Proof of Concept Study 18%
24. Apoptosis Regulatory Proteins 17%
25. Extracellular Vesicles 17%
26. T-Lymphocytes 17%
27. Oxidative Stress 16%
28. Therapeutics 15%
29. 3' Untranslated Regions 15%
30. Blood Proteins 15%
31. Chemokine Receptors 15%
32. Cell Proliferation 15%
33. Immunosuppressive Agents 14%
34. Pars Compacta 14%
35. In Vitro Techniques 14%
36. C Chemokines 13%
37. Knockout Mice 13%
38. Brain 13%
39. oxidized low density lipoprotein 13%
40. Immunotherapy 13%
41. MicroRNAs 12%
42. Biomarkers 12%
43. Phenotype 11%
44. Neurodegenerative Diseases 11%
45. Serum 11%
46. CX3C Chemokine Receptor 1 11%
47. Phagocytosis 10%
48. Induced Pluripotent Stem Cells 9%
49. Cytokines 9%
50. Intranasal Administration 9%